

# Zinc Polymorphism in Type 2 Diabetes

*Ananda S. Prasad, M.D. Ph.D.  
Distinguished Professor, Department of  
Oncology*

*American College of Nutrition  
San Diego, Nov. 2016*

WAYNE STATE  
UNIVERSITY  
SCHOOL OF MEDICINE

# Faculty Disclosure

---

<b>Commercial Interest</b>	<b>Nature of Relevant Financial Relationship (Include all those that apply)</b>	
	<b>What was received</b>	<b>For what role</b>
• None	• N/A	N/A

# Presentation Learning Objectives

---


After participating in this presentation, learners should be better able to:

- Understand role of zinc in insulin signaling
- Recognize that zinc deficiency is common in diabetes type 2 patients
- Understand the role of zinc in insulin resistance

# Zinc Deficiency in Microorganisms, Plants and Animals

1. RAULIN in 1869 - *Aspergillus niger*
2. SOMMER and LIPMAN in 1926 - Higher Plant Life
3. TODD, ELVEHJEM & HART in 1934 - Rats
4. TUCKER and SALMON in 1955 - Pigs
5. O'DELL and SAVAGE in 1958 - Poultry
6. Prasad et al in 1963 - Man

Prasad, A. S., Zinc Metabolism,  
C. C. Thomas, Springfield, Ill., 1966



**NUTRITION CLASSICS**

**THE  
AMERICAN JOURNAL  
OF MEDICINE**

**Volume 31, 1961**

**Pages 532-546**

**Syndrome of Iron Deficiency Anemia,  
Hepatosplenomegaly, Hypogonadism, Dwarfism  
and Geophagia**

**ANANDA S. PRASAD, M.D., JAMES A. HALSTED, M.D. and  
MANUCHER NADIMI, M.D.**

*Shiraz, Iran*





## Zinc-Deficient Farm Boy



LANDMARK ARTICLE

The Journal of

LABORATORY and CLINICAL MEDICINE

*Volume 61 Number 4 APRIL 1963*

Clinical and experimental

**Zinc metabolism in patients with the**

**syndrome of iron deficiency anemia, hepatosplenomegaly,**

**dwarfism, and hypogonadism**

ANANDA S. PRASAD, AUGUST MIALE, JR., Z. FARID, H. H.  
SANDSTEAD, and ARTHUR R. SCHULERT *Cairo, U. A. R.*



# CLINICAL MANIFESTATIONS IN ZINC DEFICIENT DWARFS


1. Growth Retardation
2. Hypogonadism in Males
3. Rough Skin
4. Poor Appetite
5. Mental Lethargy
6. Intercurrent Infections

## Prevalence of ZINC DEFICIENCY

**Nearly two billion subjects in the developing world have nutritional deficiency of zinc. In the developing world the diet consists of mainly cereal proteins with high phytate content which complexes zinc and decreases its availability.**

**Conditioned deficiency of zinc is also widely prevalent throughout the world. Zinc deficiency has been reported in patients with liver disease, chronic alcoholism, malabsorption syndrome, chronic renal disease, and other chronic diseases including malignancy.**

# Estimated Percentage of Population at Risk of Zinc Deficiency




Brown, et al Food Nutr Bull 2001;22:113-25

# Patient With Severe Zinc Deficiency

Alopecia




Orbital and perioral  
acanthosis





# Photograph of Patient After Zinc Therapy



# “ Mild” Deficiency of Zinc

## Manifestations:

Neuro-sensory changes

Decreased serum testosterone

Oligospermia

Hyperammonemia

Anergy

Decreased NK activity

Decreased production of IL-2

Decreased thymulin activity

Impaired cognitive functions


## Observed in:

Experimental human model studies.


Elderly

Pre-menopausal women

Lymphoid vs Myeloid Interactions;  $\longrightarrow$  Enhanced;  $\dashrightarrow$  Inhibited






# Effect of Zinc on NF- $\kappa$ B Activation in HUT-78 Cells





## REDUCTION OF MOLECULAR DIOXYGEN



## **Therapeutic Impact of the Discovery of Essentiality of Zinc in Human**

- 1. In infants and children in developing countries with acute diarrhea and respiratory tract infections**
- 2. Wilson's Disease**
- 3. Common Cold**
- 4. Sickle Cell Disease**
- 5. Prevention of blindness due to age related macular degeneration (AMD)**
- 6. Acyzol for Co poisoning (*Russian Study*)**
- 7. Decreased incidence of infections in the elderly**

# Zinc supplementation in children with Acute Diarrhea

- Sazwal et al J Nutr 126: 443-450, 1996

For infants and children with acute diarrhea, zinc supplementation results in clinically significant reductions in the duration and severity of diarrhea.

20 mg elemental zinc daily resulted in 23% reduction in the risk of continued diarrhea and 34% reduction in mean number of watery stools per day

# Zinc supplementation in children with Acute Diarrhea


- Fischer, et al. Zinc and Infectious Disease: In L Rink ed Zinc in human health, IOS Press, 2011

Zinc supplementation is recommended by WHO as an effective agent for the treatment of diarrhea and its prevention in children under 5 y of age.


WHO recommends this treatment for young children. This therapy also decreases risk of respiratory tract infections in young children.




# Effect of zinc and placebo supplementation on incidence of infection in elderly subjects after 12M of supplementation




# Effect of zinc supplementation on plasma hsCRP in elderly after 6M of supplementation



# Effect of zinc supplementation on plasma MDA+HAE in elderly after 6M of supplementation



# Effect of zinc supplementation on IL-2 mRNA in PMNC isolated from elderly after 6M of supplementation









Table 1

Zinc in the Plasma, Lymphocytes, Granulocytes, Platelets and Urine and Nucleoside Phosphorylase Activity in the Lymphocytes in Diabetic and Control Subjects


	Plasma µg/dl	Lymphocytes µg/10 <sup>10</sup> cells	Granulocytes µg/10 <sup>10</sup> cells	Z I N C (Mean ± SD)		Urine mg/g creatinine	Nucleoside Phosphor- ylase Activity in Lymphocytes ΔOD/h/mg protein (Mean ± SD)
				Platelets µg/10 <sup>10</sup> cells	mg/24hr		
Diabetic subjects	108.3±12.9 (16)	44.6±7.42 (16)	35.6±5.86 (16)	1.49±0.29 (16)	0.92±0.61 (14)	0.71±0.64 (14)	3.22±0.93 (11)
Controls	120.2±7.9 (19)	58.0±5.49 (19)	45.0±5.59 (19)	1.93±0.40 (19)	0.26±0.19 (10)	0.17±0.12 (10)	4.1±0.32 (9)
P	<.01	<.001	<.001	<.001	<.003	<.015	<.01

Note: Number in parenthesis indicates number of subjects.


# Insulin Signaling



## Impaired Insulin Secretion



# Requirement of Zinc for Insulin Synthesis



# Presentation Clinical Actions

---

After participating in this presentation, clinicians should be better able to:

- Monitor and manage zinc status in Type 2 diabetes patients
- Understand the clinical effects of zinc supplementation in Type 2 diabetes patients